Zobrazeno 1 - 10
of 21
pro vyhledávání: '"van Helden PM"'
Autor:
King LA; Department of Medical Oncology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands., de Jong M; Department of Medical Oncology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands., Veth M; Department of Medical Oncology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands., Lutje Hulsik D; Lava Therapeutics NV, Utrecht, Netherlands., Yousefi P; Lava Therapeutics NV, Utrecht, Netherlands., Iglesias-Guimarais V; Lava Therapeutics NV, Utrecht, Netherlands., van Helden PM; Lava Therapeutics NV, Utrecht, Netherlands., de Gruijl TD; Department of Medical Oncology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands., van der Vliet HJ; Department of Medical Oncology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Amsterdam, Netherlands.; Lava Therapeutics NV, Utrecht, Netherlands.
Publikováno v:
Frontiers in oncology [Front Oncol] 2024 Oct 18; Vol. 14, pp. 1474007. Date of Electronic Publication: 2024 Oct 18 (Print Publication: 2024).
Autor:
Hoving D; Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands. d.hoving@lumc.nl., Marques AHC; Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands., Huisman W; Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands., Nosoh BA; Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands., de Kroon AC; Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands., van Hengel ORJ; Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands., Wu BR; Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands., Steenbergen RAM; Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands., van Helden PM; AIMM Therapeutics, Amsterdam, The Netherlands., Urban BC; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.; Oxford Vaccine Group, University of Oxford, Oxford, UK., Dhar N; Vaccines & Infectious Diseases Analytics, University of Witwatersrand, Johannesburg, South Africa., Ferreira DM; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.; Oxford Vaccine Group, University of Oxford, Oxford, UK., Kwatra G; Vaccines & Infectious Diseases Analytics, University of Witwatersrand, Johannesburg, South Africa.; Department of Clinical Microbiology, Christian Medical College, Vellore, India., Hokke CH; Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands., Jochems SP; Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands. s.p.jochems@lumc.nl.
Publikováno v:
Communications biology [Commun Biol] 2023 Oct 28; Vol. 6 (1), pp. 1095. Date of Electronic Publication: 2023 Oct 28.
Autor:
Lubich C; R & D, Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienne, Austria.; Institute Krems Bioanalytics, University of Applied Sciences Krems, Krems, Austria., Steinitz KN; R & D, Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienne, Austria., Hoelbl B; R & D, Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienne, Austria., Prenninger T; R & D, Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienne, Austria., van Helden PM; R & D, Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienne, Austria., Weiller M; R & D, Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienne, Austria., Reipert BM; R & D, Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienne, Austria.; Institute Krems Bioanalytics, University of Applied Sciences Krems, Krems, Austria.
Publikováno v:
Frontiers in immunology [Front Immunol] 2022 Oct 21; Vol. 13, pp. 975680. Date of Electronic Publication: 2022 Oct 21 (Print Publication: 2022).
Autor:
de Jong G; AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands.; Department of Hematology, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands.; Cancer Center Amsterdam (CCA), Amsterdam, The Netherlands.; Amsterdam Infection and Immunity Institute (AI&II), Amsterdam, The Netherlands., Bartels L; AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands.; Amsterdam Infection and Immunity Institute (AI&II), Amsterdam, The Netherlands., Kedde M; AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands., Verdegaal EME; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands., Gillissen MA; AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands.; Department of Hematology, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands.; Cancer Center Amsterdam (CCA), Amsterdam, The Netherlands.; Amsterdam Infection and Immunity Institute (AI&II), Amsterdam, The Netherlands., Levie SE; AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands., Cercel MG; AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands., van Hal-van Veen SE; AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands., Fatmawati C; AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands., van de Berg D; AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands., Yasuda E; AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands., Claassen YB; AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands., Bakker AQ; AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands., van der Burg SH; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands., Schotte R; AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands., Villaudy J; AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands., Spits H; AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands.; Amsterdam Infection and Immunity Institute (AI&II), Amsterdam, The Netherlands.; Department of Experimental Immunology, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands., Hazenberg MD; Department of Hematology, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands.; Cancer Center Amsterdam (CCA), Amsterdam, The Netherlands.; Amsterdam Infection and Immunity Institute (AI&II), Amsterdam, The Netherlands.; Department of Hematopoiesis, Sanquin Research, Amsterdam, The Netherlands., van Helden PM; AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands. pmvanhelden@aimmtherapeutics.com., Wagner K; AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands.
Publikováno v:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 Jun; Vol. 70 (6), pp. 1569-1581. Date of Electronic Publication: 2020 Nov 23.
Autor:
Bartels L; AIMM Therapeutics, Amsterdam, the Netherlands.; Department of Experimental Immunology, Amsterdam University Medical Center, Location AMC, Amsterdam, the Netherlands.; Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands., de Jong G; AIMM Therapeutics, Amsterdam, the Netherlands.; Department of Experimental Immunology, Amsterdam University Medical Center, Location AMC, Amsterdam, the Netherlands.; Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Amsterdam, the Netherlands.; Department of Hematology, Amsterdam University Medical Center, Location AMC, Amsterdam, the Netherlands., Gillissen MA; AIMM Therapeutics, Amsterdam, the Netherlands.; Department of Experimental Immunology, Amsterdam University Medical Center, Location AMC, Amsterdam, the Netherlands.; Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Amsterdam, the Netherlands.; Department of Hematology, Amsterdam University Medical Center, Location AMC, Amsterdam, the Netherlands., Yasuda E; AIMM Therapeutics, Amsterdam, the Netherlands., Kattler V; AIMM Therapeutics, Amsterdam, the Netherlands., Bru C; AIMM Therapeutics, Amsterdam, the Netherlands., Fatmawati C; AIMM Therapeutics, Amsterdam, the Netherlands., van Hal-van Veen SE; AIMM Therapeutics, Amsterdam, the Netherlands., Cercel MG; AIMM Therapeutics, Amsterdam, the Netherlands., Moiset G; AIMM Therapeutics, Amsterdam, the Netherlands.; Department of Experimental Immunology, Amsterdam University Medical Center, Location AMC, Amsterdam, the Netherlands.; Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Amsterdam, the Netherlands.; Department of Hematology, Amsterdam University Medical Center, Location AMC, Amsterdam, the Netherlands., Bakker AQ; AIMM Therapeutics, Amsterdam, the Netherlands., van Helden PM; AIMM Therapeutics, Amsterdam, the Netherlands., Villaudy J; AIMM Therapeutics, Amsterdam, the Netherlands., Hazenberg MD; Department of Experimental Immunology, Amsterdam University Medical Center, Location AMC, Amsterdam, the Netherlands.; Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Amsterdam, the Netherlands.; Department of Hematology, Amsterdam University Medical Center, Location AMC, Amsterdam, the Netherlands., Spits H; AIMM Therapeutics, Amsterdam, the Netherlands.; Department of Experimental Immunology, Amsterdam University Medical Center, Location AMC, Amsterdam, the Netherlands.; Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands., Wagner K; AIMM Therapeutics, Amsterdam, the Netherlands. kwagner@aimmtherapeutics.com.
Publikováno v:
Cancer research [Cancer Res] 2019 Jul 01; Vol. 79 (13), pp. 3372-3382. Date of Electronic Publication: 2019 May 07.
Autor:
Gillissen MA; AIMM Therapeutics and.; Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands., Kedde M; AIMM Therapeutics and., Jong G; Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands., Moiset G; AIMM Therapeutics and.; Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands., Yasuda E; AIMM Therapeutics and., Levie SE; AIMM Therapeutics and., Bakker AQ; AIMM Therapeutics and., Claassen YB; AIMM Therapeutics and., Wagner K; AIMM Therapeutics and., Böhne M; AIMM Therapeutics and., Hensbergen PJ; Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands; and., Speijer D; Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands., van Helden PM; AIMM Therapeutics and., Beaumont T; AIMM Therapeutics and., Spits H; AIMM Therapeutics and., Hazenberg MD; Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands.
Publikováno v:
Blood [Blood] 2018 Jan 04; Vol. 131 (1), pp. 131-143. Date of Electronic Publication: 2017 Oct 23.
Autor:
Gillissen MA; AIMM Therapeutics, Amsterdam, The Netherlands.; Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands., de Jong G; AIMM Therapeutics, Amsterdam, The Netherlands.; Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands., Kedde M; AIMM Therapeutics, Amsterdam, The Netherlands., Yasuda E; AIMM Therapeutics, Amsterdam, The Netherlands., Levie SE; AIMM Therapeutics, Amsterdam, The Netherlands., Moiset G; AIMM Therapeutics, Amsterdam, The Netherlands., Hensbergen PJ; Center for Proteomics and Metabolomics, University Medical Center, Leiden, The Netherlands; and., Bakker AQ; AIMM Therapeutics, Amsterdam, The Netherlands., Wagner K; AIMM Therapeutics, Amsterdam, The Netherlands., Villaudy J; AIMM Therapeutics, Amsterdam, The Netherlands., van Helden PM; AIMM Therapeutics, Amsterdam, The Netherlands., Spits H; AIMM Therapeutics, Amsterdam, The Netherlands.; Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands., Hazenberg MD; Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands.; Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.
Publikováno v:
Blood advances [Blood Adv] 2017 Aug 18; Vol. 1 (19), pp. 1551-1564. Date of Electronic Publication: 2017 Aug 18 (Print Publication: 2017).
Autor:
Gillissen MA; AIMM Therapeutics, Academic Medical Center, Amsterdam, The Netherlands.; Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands., de Jong G; AIMM Therapeutics, Academic Medical Center, Amsterdam, The Netherlands.; Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands., Levie SE; AIMM Therapeutics, Academic Medical Center, Amsterdam, The Netherlands., Yasuda E; AIMM Therapeutics, Academic Medical Center, Amsterdam, The Netherlands., Bakker AQ; AIMM Therapeutics, Academic Medical Center, Amsterdam, The Netherlands., Evers LM; Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands., Pals ST; Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands., Huisman C; Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands., van Helden PM; AIMM Therapeutics, Academic Medical Center, Amsterdam, The Netherlands., Spits H; AIMM Therapeutics, Academic Medical Center, Amsterdam, The Netherlands., Hazenberg MD; Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands.
Publikováno v:
Bone marrow transplantation [Bone Marrow Transplant] 2016 Sep; Vol. 51 (9), pp. 1245-8. Date of Electronic Publication: 2016 Apr 18.
Autor:
Gillissen MA; AIMM Therapeutics, Academic Medical Center, Amsterdam, The Netherlands; Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands., Yasuda E; AIMM Therapeutics, Academic Medical Center, Amsterdam, The Netherlands., de Jong G; AIMM Therapeutics, Academic Medical Center, Amsterdam, The Netherlands; Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands., Levie SE; AIMM Therapeutics, Academic Medical Center, Amsterdam, The Netherlands., Go D; AIMM Therapeutics, Academic Medical Center, Amsterdam, The Netherlands., Spits H; AIMM Therapeutics, Academic Medical Center, Amsterdam, The Netherlands., van Helden PM; AIMM Therapeutics, Academic Medical Center, Amsterdam, The Netherlands., Hazenberg MD; Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: m.d.hazenberg@amc.nl.
Publikováno v:
Journal of immunological methods [J Immunol Methods] 2016 Jul; Vol. 434, pp. 16-23. Date of Electronic Publication: 2016 Apr 13.
Autor:
Kwakkenbos MJ; AIMM Therapeutics, Academic Medical Center, Amsterdam, The Netherlands., van Helden PM; AIMM Therapeutics, Academic Medical Center, Amsterdam, The Netherlands., Beaumont T; AIMM Therapeutics, Academic Medical Center, Amsterdam, The Netherlands., Spits H; AIMM Therapeutics, Academic Medical Center, Amsterdam, The Netherlands.; Department of Cell Biology and Histology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Publikováno v:
Immunological reviews [Immunol Rev] 2016 Mar; Vol. 270 (1), pp. 65-77.